
    
      This is a single center, double blind (patients and investigators), Placebo controlled
      randomized trial.

      Consecutive patients with Psoriatic Arthritis (PsA) in moderate disease activity (Psoriatic
      Arthritis Disease Activity Score: PASDAS >3.2 - <5.4) on a stable treatment (no
      immunomodulatory treatment change in the last 3 months) with biological (bDMARDs) and/or
      synthetic disease modifying anti-rheumatic drugs (sDMARDs) and/or glucocorticoids will be
      included in the study. Clinical assessment will be scheduled at baseline, 12 weeks and 24
      weeks.
    
  